1	Clinical	Clinical	B-NP	JJ	O	2	NMOD	-1
2	significance	significance	I-NP	NN	O	0	ROOT	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	plasma	plasma	B-NP	NN	B-protein	5	NMOD	-1
5	endostatin	endostatin	I-NP	NN	I-protein	3	PMOD	-1
6	in	in	B-PP	IN	O	2	NMOD	-1
7	acute	acute	B-NP	JJ	O	10	NMOD	-1
8	myeloid	myeloid	I-NP	JJ	O	10	NMOD	-1
9	leukemia/myelodysplastic	leukemia/myelodysplastic	I-NP	JJ	O	10	NMOD	-1
10	syndrome	syndrome	I-NP	NN	O	6	PMOD	-1
11	.	.	O	.	O	2	P	-1

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Endostatin	Endostatin	B-NP	NN	B-protein	7	NMOD	-1
4	,	,	O	,	O	7	P	-1
5	a	a	B-NP	DT	O	7	NMOD	-1
6	C-terminal	C-terminal	I-NP	JJ	B-protein	7	NMOD	-1
7	fragment	fragment	I-NP	NN	I-protein	1	NMOD	-1
8	of	of	B-PP	IN	O	7	NMOD	-1
9	collagen	collagen	B-NP	NN	B-protein	10	NMOD	-1
10	XVIII	XVIII	I-NP	NN	I-protein	8	PMOD	-1
11	,	,	O	,	O	7	P	-1
12	is	be	B-VP	VBZ	O	1	NMOD	-1
13	an	an	B-NP	DT	O	16	NMOD	-1
14	endogenous	endogenous	I-NP	JJ	O	16	NMOD	-1
15	angiogenesis	angiogenesis	I-NP	NN	O	16	NMOD	3	angiogenesis
16	inhibitor	inhibitor	I-NP	NN	O	12	PRD	0
17	.	.	O	.	O	12	P	-1

1	While	While	B-SBAR	IN	O	19	VMOD	-1
2	endostatin	endostatin	B-NP	NN	B-protein	3	SUB	-1
3	is	be	B-VP	VBZ	O	1	SBAR	-1
4	being	be	I-VP	VBG	O	3	VC	-1
5	investigated	investigate	I-VP	VBN	O	4	VC	-1
6	for	for	B-PP	IN	O	5	VMOD	-1
7	its	its	B-NP	PRP$	O	8	NMOD	-1
8	usefulness	usefulness	I-NP	NN	O	6	PMOD	-1
9	in	in	B-PP	IN	O	5	VMOD	-1
10	treating	treat	B-VP	VBG	O	9	PMOD	19	treating
11	solid	solid	B-NP	JJ	O	12	NMOD	-1
12	tumors	tumor	I-NP	NNS	O	10	OBJ	-1
13	,	,	O	,	O	19	P	-1
14	its	its	B-NP	PRP$	O	15	NMOD	-1
15	significance	significance	I-NP	NN	O	19	SUB	-1
16	in	in	B-PP	IN	O	15	NMOD	-1
17	hematologic	hematologic	B-NP	JJ	O	18	NMOD	-1
18	malignancies	malignancy	I-NP	NNS	O	16	PMOD	-1
19	is	be	B-VP	VBZ	O	0	ROOT	-1
20	unknown	unknown	B-ADJP	JJ	O	19	PRD	-1
21	.	.	O	.	O	19	P	-1

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	The	The	B-NP	DT	O	4	NMOD	-1
4	authors	author	I-NP	NNS	O	5	SUB	-1
5	evaluated	evaluate	B-VP	VBD	O	1	NMOD	-1
6	plasma	plasma	B-NP	NN	O	7	NMOD	-1
7	endostatin	endostatin	I-NP	NN	O	11	NMOD	-1
8	(	(	O	(	O	10	DEP	-1
9	PE	PE	B-NP	NN	O	10	DEP	-1
10	)	)	O	)	O	7	NMOD	-1
11	levels	level	B-NP	NNS	O	5	OBJ	-1
12	using	use	B-VP	VBG	O	5	VMOD	-1
13	an	an	B-NP	DT	O	16	NMOD	-1
14	enzyme	enzyme	I-NP	NN	O	16	NMOD	-1
15	linked	link	I-NP	VBN	O	16	NMOD	0
16	immunoassay	immunoassay	I-NP	NN	O	12	OBJ	-1
17	in	in	B-PP	IN	O	16	NMOD	-1
18	71	71	B-NP	CD	O	19	NMOD	-1
19	patients	patient	I-NP	NNS	O	17	PMOD	-1
20	with	with	B-PP	IN	O	19	NMOD	-1
21	acute	acute	B-NP	JJ	O	23	NMOD	-1
22	myeloid	myeloid	I-NP	JJ	O	23	NMOD	-1
23	leukemia	leukemia	I-NP	NN	O	29	NMOD	-1
24	(	(	O	(	O	26	DEP	-1
25	AML	AML	B-NP	NN	O	26	DEP	-1
26	)	)	O	)	O	23	NMOD	-1
27	and	and	O	CC	O	29	NMOD	-1
28	43	43	B-NP	CD	O	29	NMOD	-1
29	patients	patient	I-NP	NNS	O	20	PMOD	-1
30	with	with	B-PP	IN	O	29	NMOD	-1
31	myelodysplastic	myelodysplastic	B-NP	JJ	O	32	NMOD	-1
32	syndrome	syndrome	I-NP	NN	O	30	PMOD	-1
33	(	(	O	(	O	35	DEP	-1
34	MDS	MDS	B-NP	NN	O	35	DEP	-1
35	)	)	O	)	O	32	NMOD	-1
36	,	,	O	,	O	5	P	-1
37	and	and	O	CC	O	5	VMOD	-1
38	correlated	correlate	B-VP	VBD	O	5	VMOD	-1
39	PE	PE	B-NP	NN	O	38	OBJ	-1
40	with	with	B-PP	IN	O	38	VMOD	-1
41	various	various	B-NP	JJ	O	43	NMOD	-1
42	clinical	clinical	I-NP	JJ	O	43	NMOD	-1
43	parameters	parameter	I-NP	NNS	O	40	PMOD	-1
44	.	.	O	.	O	1	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	There	There	B-NP	EX	O	4	SUB	-1
4	was	be	B-VP	VBD	O	1	NMOD	-1
5	no	no	B-NP	DT	O	7	NMOD	-1
6	significant	significant	I-NP	JJ	O	7	NMOD	-1
7	difference	difference	I-NP	NN	O	4	PRD	-1
8	in	in	B-PP	IN	O	7	NMOD	-1
9	the	the	B-NP	DT	O	12	NMOD	-1
10	median	median	I-NP	JJ	O	12	NMOD	-1
11	PE	PE	I-NP	NN	O	12	NMOD	-1
12	level	level	I-NP	NN	O	8	PMOD	-1
13	between	between	B-PP	IN	O	7	NMOD	-1
14	AML/MDS	AML/MDS	B-NP	NN	O	15	NMOD	-1
15	patients	patient	I-NP	NNS	O	19	NMOD	-1
16	and	and	O	CC	O	19	NMOD	-1
17	the	the	B-NP	DT	O	19	NMOD	-1
18	normal	normal	I-NP	JJ	O	19	NMOD	-1
19	controls	control	I-NP	NNS	O	13	PMOD	0
20	.	.	O	.	O	1	P	-1

1	Nevertheless	Nevertheless	B-ADVP	RB	O	11	VMOD	-1
2	,	,	O	,	O	11	P	-1
3	patients	patient	B-NP	NNS	O	11	SUB	-1
4	who	who	B-NP	WP	O	3	NMOD	-1
5	achieved	achieve	B-VP	VBD	O	4	SBAR	-1
6	complete	complete	B-NP	JJ	O	7	NMOD	-1
7	remission	remission	I-NP	NN	O	5	OBJ	-1
8	(	(	O	(	O	10	DEP	-1
9	CR	CR	B-NP	NN	O	10	DEP	-1
10	)	)	O	)	O	3	NMOD	-1
11	had	have	B-VP	VBD	O	0	ROOT	-1
12	a	a	B-NP	DT	O	17	NMOD	-1
13	significantly	significantly	I-NP	RB	O	14	AMOD	-1
14	lower	low	I-NP	JJR	O	15	AMOD	-1
15	median	median	I-NP	JJ	O	17	NMOD	-1
16	PE	PE	I-NP	NN	O	17	NMOD	-1
17	level	level	I-NP	NN	O	11	OBJ	-1
18	compared	compare	B-VP	VBN	O	11	VMOD	-1
19	to	to	B-PP	TO	O	18	PMOD	-1
20	those	those	B-NP	DT	O	19	PMOD	-1
21	who	who	B-NP	WP	O	20	NMOD	-1
22	did	do	B-VP	VBD	O	21	SBAR	-1
23	not	not	O	RB	O	22	VMOD	-1
24	.	.	O	.	O	11	P	-1

1	In	In	B-PP	IN	O	6	VMOD	-1
2	multivariate	multivariate	B-NP	JJ	O	3	NMOD	-1
3	analysis	analysis	I-NP	NN	O	1	PMOD	-1
4	,	,	O	,	O	6	P	-1
5	PE	PE	B-NP	NN	O	6	SUB	-1
6	was	be	B-VP	VBD	O	0	ROOT	-1
7	found	find	I-VP	VBN	O	6	VC	0
8	to	to	I-VP	TO	O	9	VMOD	-1
9	be	be	I-VP	VB	O	7	VMOD	-1
10	a	a	B-NP	DT	O	11	NMOD	-1
11	significant	significant	I-NP	JJ	O	44	NMOD	-1
12	(	(	O	(	O	16	DEP	-1
13	P	P	B-NP	NN	O	16	DEP	-1
14	=	=	B-VP	SYM	O	13	NMOD	-1
15	0.03	0.03	B-NP	CD	O	14	AMOD	-1
16	)	)	O	)	O	11	NMOD	-1
17	predictor	predictor	B-NP	NN	O	11	NMOD	-1
18	of	of	B-PP	IN	O	11	NMOD	-1
19	overall	overall	B-NP	JJ	O	20	NMOD	-1
20	survival	survival	I-NP	NN	O	18	PMOD	0
21	(	(	O	(	O	23	DEP	-1
22	OS	OS	B-NP	NN	O	23	DEP	-1
23	)	)	O	)	O	20	NMOD	-1
24	with	with	B-PP	IN	O	20	NMOD	-1
25	adjustment	adjustment	B-NP	NN	O	24	PMOD	-1
26	of	of	B-PP	IN	O	25	NMOD	-1
27	the	the	B-NP	DT	O	30	NMOD	-1
28	other	other	I-NP	JJ	O	30	NMOD	-1
29	baseline	baseline	I-NP	NN	O	30	NMOD	-1
30	covariates	covariate	I-NP	NNS	O	26	PMOD	-1
31	,	,	O	,	O	30	P	-1
32	including	include	B-PP	VBG	O	30	NMOD	-1
33	patient	patient	B-NP	NN	O	34	NMOD	-1
34	age	age	I-NP	NN	O	36	NMOD	-1
35	,	,	O	,	O	36	P	-1
36	history	history	B-NP	NN	O	32	PMOD	-1
37	of	of	B-PP	IN	O	36	NMOD	-1
38	antecedent	antecedent	B-NP	JJ	O	40	NMOD	-1
39	hematologic	hematologic	I-NP	JJ	O	40	NMOD	-1
40	disorders	disorder	I-NP	NNS	O	37	PMOD	-1
41	,	,	O	,	O	44	P	-1
42	and	and	O	CC	O	44	NMOD	-1
43	the	the	B-NP	DT	O	44	NMOD	-1
44	use	use	I-NP	NN	O	9	PRD	0
45	of	of	B-PP	IN	O	44	NMOD	-1
46	protective	protective	B-NP	JJ	O	47	NMOD	-1
47	environments	environment	I-NP	NNS	O	45	PMOD	-1
48	.	.	O	.	O	6	P	-1

1	The	The	B-NP	DT	O	3	NMOD	-1
2	prognostic	prognostic	I-NP	JJ	O	3	NMOD	-1
3	value	value	I-NP	NN	O	6	SUB	-1
4	of	of	B-PP	IN	O	3	NMOD	-1
5	PE	PE	B-NP	NN	O	4	PMOD	-1
6	was	be	B-VP	VBD	O	0	ROOT	-1
7	also	also	I-VP	RB	O	6	VMOD	-1
8	evaluated	evaluate	I-VP	VBN	O	6	VC	-1
9	by	by	B-PP	IN	O	8	VMOD	-1
10	dividing	divide	B-VP	VBG	O	9	PMOD	0
11	MDS/AML	MDS/AML	B-NP	NN	O	12	NMOD	-1
12	patients	patient	I-NP	NNS	O	10	OBJ	-1
13	into	into	B-PP	IN	O	10	VMOD	-1
14	high	high	B-NP	JJ	O	18	NMOD	-1
15	and	and	I-NP	CC	O	18	NMOD	-1
16	low	low	I-NP	JJ	O	18	NMOD	-1
17	PE	PE	I-NP	NN	O	18	NMOD	-1
18	groups	group	I-NP	NNS	O	13	PMOD	-1
19	using	use	B-VP	VBG	O	10	VMOD	-1
20	the	the	B-NP	DT	O	23	NMOD	-1
21	median	median	I-NP	JJ	O	23	NMOD	-1
22	PE	PE	I-NP	NN	O	23	NMOD	-1
23	level	level	I-NP	NN	O	19	OBJ	-1
24	of	of	B-PP	IN	O	23	NMOD	-1
25	normal	normal	B-NP	JJ	O	26	NMOD	-1
26	controls	control	I-NP	NNS	O	24	PMOD	0
27	as	as	B-PP	IN	O	19	VMOD	-1
28	the	the	B-NP	DT	O	29	NMOD	-1
29	cut-off	cut-off	I-NP	NN	B-protein	27	PMOD	-1
30	.	.	O	.	O	6	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	authors	author	I-NP	NNS	O	3	SUB	-1
3	found	find	B-VP	VBD	O	0	ROOT	0
4	that	that	B-SBAR	IN	O	3	VMOD	-1
5	patients	patient	B-NP	NNS	O	11	SUB	-1
6	in	in	B-PP	IN	O	5	NMOD	-1
7	the	the	B-NP	DT	O	10	NMOD	-1
8	high	high	I-NP	JJ	O	10	NMOD	-1
9	PE	PE	I-NP	NN	O	10	NMOD	-1
10	group	group	I-NP	NN	O	6	PMOD	-1
11	survived	survive	B-VP	VBD	O	4	SBAR	5	survived
12	for	for	B-PP	IN	O	11	VMOD	-1
13	a	a	B-NP	DT	O	16	NMOD	-1
14	significantly	significantly	I-NP	RB	O	15	AMOD	-1
15	shorter	short	I-NP	JJR	O	16	NMOD	-1
16	time	time	I-NP	NN	O	12	PMOD	-1
17	than	than	B-PP	IN	O	11	VMOD	-1
18	those	those	B-NP	DT	O	19	NMOD	-1
19	patients	patient	I-NP	NNS	O	17	PMOD	-1
20	in	in	B-PP	IN	O	19	NMOD	-1
21	the	the	B-NP	DT	O	24	NMOD	-1
22	low	low	I-NP	JJ	O	24	NMOD	-1
23	PE	PE	I-NP	NN	O	24	NMOD	-1
24	group	group	I-NP	NN	O	20	PMOD	-1
25	.	.	O	.	O	3	P	-1

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	PE	PE	B-NP	NN	O	4	SUB	-1
4	is	be	B-VP	VBZ	O	1	NMOD	-1
5	a	a	B-NP	DT	O	8	NMOD	-1
6	useful	useful	I-NP	JJ	O	8	NMOD	-1
7	prognostic	prognostic	I-NP	JJ	O	8	NMOD	-1
8	predictor	predictor	I-NP	NN	O	4	PRD	-1
9	of	of	B-PP	IN	O	8	NMOD	-1
10	CR	CR	B-NP	NN	O	12	NMOD	-1
11	and	and	I-NP	CC	O	12	NMOD	-1
12	OS	OS	I-NP	NN	O	9	PMOD	-1
13	for	for	B-PP	IN	O	12	NMOD	-1
14	AML/MDS	AML/MDS	B-NP	NN	O	15	NMOD	-1
15	patients	patient	I-NP	NNS	O	13	PMOD	-1
16	.	.	O	.	O	1	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	mechanism	mechanism	I-NP	NN	O	13	SUB	0
3	underlying	underlie	B-VP	VBG	O	2	NMOD	-1
4	the	the	B-NP	DT	O	5	NMOD	-1
5	association	association	I-NP	NN	O	3	OBJ	0
6	between	between	B-PP	IN	O	5	NMOD	-1
7	high	high	B-NP	JJ	O	8	NMOD	-1
8	PE	PE	I-NP	NN	O	12	NMOD	-1
9	and	and	O	CC	O	12	NMOD	-1
10	poor	poor	B-NP	JJ	O	11	AMOD	-1
11	clinical	clinical	I-NP	JJ	O	12	NMOD	-1
12	outcome	outcome	I-NP	NN	O	6	PMOD	-1
13	is	be	B-VP	VBZ	O	0	ROOT	-1
14	unclear	unclear	B-ADJP	JJ	O	13	PRD	-1
15	,	,	O	,	O	13	P	-1
16	although	although	B-SBAR	IN	O	13	VMOD	-1
17	it	it	B-NP	PRP	O	18	SUB	-1
18	may	may	B-VP	MD	O	16	SBAR	-1
19	be	be	I-VP	VB	O	18	VC	-1
20	related	related	B-ADJP	JJ	O	19	PRD	-1
21	to	to	B-PP	TO	O	20	AMOD	-1
22	the	the	B-NP	DT	O	25	NMOD	-1
23	possible	possible	I-NP	JJ	O	25	NMOD	-1
24	PE	PE	I-NP	NN	O	25	NMOD	-1
25	reflection	reflection	I-NP	NN	O	21	PMOD	-1
26	of	of	B-PP	IN	O	25	NMOD	-1
27	tumor	tumor	B-NP	NN	O	28	NMOD	-1
28	burden	burden	I-NP	NN	O	26	PMOD	-1
